Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib in relapsed prostate cancer
NCT00241475Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in prostate cancer (PCa), sponsored by AstraZeneca. Primary endpoint: PSA response rate. Started Dec 2003; status: completed.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00241475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00241475.